PIM
RPRX icon

Plato Investment Management’s Royalty Pharma RPRX Stock Holding History

Plato Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,503
Closed -$166K – 594
2024
Q4 		$166K Sell
6,503
-31,807
-83% -$843K 0.01% 423
2024
Q3 		$1.08M Hold
38,310
– – 0.09% 233
2024
Q2 		$1.01M Hold
38,310
– – 0.09% 206
2024
Q1 		$1.16M Buy
+38,310
New +$1.13M 0.12% 187

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Plato Investment Management's RPRX Position: Q1 2025 in Review

Plato Investment Management sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 6,503 shares — an estimated $166K sold.

Plato Investment Management first reported a position in RPRX in Q1 2024 and held it in 4 quarters. The position peaked at $1.16M in Q1 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

  • Plato Investment Management reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
  • Plato Investment Management sold 6,503 Royalty Pharma shares in Q1 2025, an estimated $166K.
  • Plato Investment Management first reported a position in Royalty Pharma in Q1 2024 and held it in 4 quarters.
  • Plato Investment Management's Royalty Pharma position peaked at $1.16M in Q1 2024.
  • 447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Plato Investment Management's 13F filing for Q1 2025, filed 20 May 2025.